Sixty-three patients with paralysis secondary to spinal cord injury (SCI) were screened for heterotopic ossi®cation (HO) by bone scintigraphy 27+14 (mean+SD) days after SCI. There were four female and 59 male patients, 36 had paraplegia and 27 tetraplegia. The age of patients was 28+9 years. Bone scintigraphy was obtained with a 3-phase test using 99m-technetium labeled diphosphonate, and the positive third phase was used as a criterion for diagnosis of HO. Bone scintigraphy was negative for HO in 27 patients (14 tetraplegic and 13 paraplegic) and positive in 36 patients (13 tetraplegic and 23 paraplegic). The patients with positive HO were treated with etidronate, ®rst with an intravenous dose of 300 mg/day for 3 days, and then with an oral dose of 20 mg/kg/day for 6 months. The follow-up of patients consisted of clinical and radiographic evaluations every 2 ± 4 months. The extent of HO was classi®ed radiographically. In the treated group of patients who completed the entire course of etidronate therapy one patient developed HO, the remaining 28 (97%) patients had no radiographic evidence of HO during the follow-up of 10.6+4.5 months after initiation of therapy.
Introduction
Heterotopic ossi®cation (HO) is a common complication after spinal cord injury (SCI) which occurs in paralyzed limbs. The incidence of HO after SCI is approximately 50%; 1 ± 4 in 10 ± 20% of these patients, HO develops in a more severe form which usually requires surgical therapy. 5, 6 In other patients with less severe soft tissue ossi®cation, HO may cause variable degrees of functional limitations in aected joints. Because the etiology of HO is uncertain, it is dicult to design an eective diagnostic or therapeutic protocol in its management. Based on the results obtained from the studies in animals, it seems that in the pathogenesis of HO, certain osteoinductive factors capable of stimulating dierentiation of soft tissue mesenchymal cells into bone forming cells play an important role. 7 ± 9 The osteoinductive and mitogenic activities have been identi®ed in the serum of some patients with spinal cord 10, 11 and brain injury 12 who are prone to develop HO, but biochemical characteristics and the mechanism of action of these substances are presently unknown.
The most commonly used tests in the diagnosis of HO are radiography and bone scintigraphy. Although radiographic examination is more speci®c than bone scintigraphy in the diagnosis of bone pathology, the latter test is more sensitive in the diagnosis of many skeletal diseases including HO. In the early stages of HO the bone consists mainly of osteoid which is readily detectable by bone scintigraphy and will become positive on radiographic evaluation upon accumulation of more minerals about 2 ± 4 weeks later. 13, 14 The results of these imaging studies are important in the therapy of patients, because etidronate, the most commonly used drug in the therapy of HO in patients after SCI, has an inhibitory eect on the formation of calcium phosphate crystals. 15, 16 Therefore, several groups of investigators have recommended an initiation of therapy in the earliest possible stages while HO is predominantly in an unmineralized form. 13,14,17 ± 19 The use of bone scintigraphy in the diagnosis of HO has also been suggested in order to detect HO in the initial stage of its evolution. 13, 14, 20, 21 In the present study we report an eective management of HO which was based on the screening of asymptomatic patients by bone scintigraphy, consequently resulting in considerable better prevention of HO than reported in previous studies where the diagnosis of HO was based on the radiographic examination.
Methods

Patients
We studied a group of 63 nonselected and consecutive patients after SCI. They were divided into two groups based on the results of bone scintigraphy. Positive HO on bone scintigraphy was found in 36 patients (57%), negative HO was found in 27 patients (43%). In the group of 36 patients with positive scintigraphic ®ndings, there were 23 patients with paraplegia and 13 with tetraplegia. The degree of impairment was graded by American Spinal Injury Association (ASIA) scale. 22 The age of patients was 29+11 years (mean+SD), (range: 19 ± 56 years). In the group with positive scintigraphic HO ®ndings 25 patients had ASIA impairment score A, seven score B, and four score C. In the group of patients with negative HO ®ndings on bone scintigraphy, there were 13 patients with paraplegia and 14 with tetraplegia. The age of patients was 25+7 years (range: 18 ± 48). There were 17 patients with ASIA impairment score of A, four with score B, and six with score C.
Bone scintigraphy
Bone scintigraphy was performed by a 3-phase test using 99m technetium labeled methylene diphosphonate (99mTc-MDP). The test was done 27+14 days after SCI (range 10 ± 69) days. At the time of bone scintigraphy all patients were asymptomatic without clinical manifestations of HO such as swelling of the joints or asymmetric reduction of the range of motion. Bone scintigraphy was performed with the dose of 20 to 25 mCi of 99mTc-MDP. The positive third phase of the test was used as a criterion for the diagnosis of HO. Those patients with positive bone scintigraphy were evaluated radiographically in order to rule out other bone pathology.
Therapy
The patients with positive bone scintigraphy were treated with disodium etidronate (Didronel, Proctor & Gamble Pharmaceuticals, Norwich, NY). The treatment was started with intravenous and continued with oral therapy as described previously. 20 Brie¯y, the intravenous dose of 300 mg/day was administered over a period of 3 h for a total of 3 days. Prior to the intravenous medication all patients were hydrated with normal saline (250 ± 300 ml), and an indwelling catheter was inserted in order to prevent bladder distention. Following the intravenous dose of etidronate the therapy was continued with an oral dose of 20 mg/kg/day for a period of 6 months. The total oral dose of etidronate did not exceed 1200 mg/day.
Follow up of patients
The group of patients with positive scintigraphic ®ndings of HO was followed clinically and by radiographic examination of aected joints every 2 to 4 months. The extent of soft tissue ossi®cation was determined radiographically using classi®cation of Garland et al. 6 The period of follow up was 10.6+4.5 months (range: 7 ± 22) after initiation of therapy. The group of patients with negative bone scintigraphy on the screening test was followed for a period of 12.5+7 months (range: 6 ± 24).
Results
In the group of patients with positive bone scintigraphy 49% had single and 51% multiple involvement of joints. Table 1 illustrates the incidence of HO at dierent sites of localization in the positive group. The soft tissue surrounding the hips was the most frequent localization of HO; in 97% of patients bone scintigraphy was positive either in one or both hips. Figure 1 summarizes the results of the therapy. In the group of 36 patients with positive HO scintigraphy, the therapy with etidronate was started at the time of diagnosis, on the average of 4 weeks after SCI. In this group, 29 patients completed a course of 6-month therapy, one patient developed HO, the remaining 28 patients (87%) had neither clinical nor radiographic evidence of HO during the follow up of 10.6+4.5 months (range: 7 ± 22). In the patient who developed HO, the extent of ossi®cation was minimal Figure 1 The results of the therapy with etidronate in patients after SCI as illustrated in Figure 2 ; HO in this patient had no eect on the range of hip motion, and it was diagnosed 16 months after therapy with etidronate. Seven patients with positive bone scintigraphy were excluded from the study because they did not complete the entire experimental protocol. Five patients were lost in follow-up, but had no HO during the 2.5+0.8 months of therapy; two patients were noncompliant and stopped taking medication, both of them developed HO of grade III after a period of 1 to 2 months.
In the group of 27 patients with negative scintigraphic ®ndings of HO, there was no clinical evidence of HO during the rehabilitation for a period of approximately 2 months. After completion of their rehabilitation, 15 out of 27 patients were followed in the clinic, three (20%) of them developed HO at time of 4, 6 and 18 months after SCI respectively. The degree of HO was grade I in two patients and grade II in one patient.
Discussion
Although the pathogenesis of HO is unknown, and the treatment of HO is symptomatic, clinical experience indicates that the bene®cial results in the management of HO could be obtained when the therapy was started in the early stage of tissue ossi®cation. 13, 20, 23 It seems clinically important that the diagnosis and therapy focus on the early stage of HO evolution, while the immature osteoid contains predominantly amorphous, non-crystalline calcium salts. HO is not detectable on radiographic examination at this stage of formation, and various other tests, such as determination of serum calcium, alkaline phosphatase, hydroxyproline, osteocalcin or osteoinductive activity, have a limited diagnostic value. 5, 10, 14, 24, 25 Several groups of investigators have shown that immature HO after SCI can be detected by bone scintigraphy. 13, 14, 20 Likewise, it was found that in the diagnosis of HO, bone scintigraphy is a more sensitive diagnostic test than radiographic examination and that the test has a high degree of speci®city in diagnosis of HO. 13, 14 Freed et al.
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reported 17 patients with positive bone scan for HO and negative radiographic ®ndings who developed HO 2 to 4 weeks in areas of increased activity on bone scan. Similarly, Orzel and Rudd studied 11 patients to determine the temporal relationship between abnormal bone scan and radiographic soft tissue ossi®cation. The radiographic HO followed positive bone scan by an average of 15 days. In a previous study we found that the early scintigraphic diagnosis of HO, and subsequent therapy with etidronate, signi®cantly reduced the incidence of HO after SCI (unpublished data). We were able to prevent HO in 79% of the patients who were started on etidronate at the time of scintigraphic diagnosis. In 21% of the patients etidronate was ineective and patients developed HO, however, the drug had an inhibitory eect on the extent of heterotopic bone formation when compared to the mass of HO in the patients who prematurely stopped the therapy. We attributed this incomplete eect of etidronate therapy to delayed diagnosis of HO. Most likely those patients who developed HO already had, at the time of scintigraphic evaluation, a larger mass of immature HO than the patients who responded to therapy. These ®ndings suggest that in an attempt to diagnose the early stage of HO formation, the diagnostic procedure should be performed prior to the development of clinical signs and symptoms of local in¯ammation. Therefore the present study was designed to evaluate the results of the therapy based on the screening of asymptomatic patients. The screening was performed by bone scintigraphy on an average of 4 weeks after injury and resulted in positive ®ndings in 57% of the patients. This incidence of HO after SCI was somewhat higher than previously reported by radiographic evaluation 1 ± 4 because the routine radiographic examination does not always include the evaluation of the entire skeletal system, as is routinely performed by bone scintigraphy. When the treatment was initiated in asymptomatic patients with positive scintigraphic ®ndings of HO, only one out of 29 patients developed a low degree of HO which was diagnosed after 16 months of follow-up.
Two important aspects of therapy with higher doses of etidronate require discussion, the incidence of side eects and the occurrence of HO after withdrawal of etidronate. In the present study we used higher doses of etidronate than routinely recommended; the initial intravenous dose of 300 mg/day for 3 days and a 6 month oral dose of 20 mg/kg/day was signi®cantly higher than commonly used initial dose of 20 mg/kg/ day for 2 weeks followed by 10 mg/kg/day for 10 weeks. 17.19.26.27 The studies in patients with Paget's disease 28, 29 documented that the administration of 20 mg/kg/day of etidronate often resulted in development of variable degrees of osteomalacia. Whether the inhibition of mineralization in SCI patients treated with the same doses of etidronate is associated with osteomalacia is unknown. Although it is likely that considerable amount of osteoid develops in the bone of these patients, based on our experience in the present and the previous study, 20 these were not serious consequences. Some of these patients were followed for a period of 3 years after the therapy and did not develop any complications. Similarly, in a group of SCI patients treated with etidronate 20 mg/ kg/day for 6 months, fractures were not noted during or after the therapy with etidronate (Garland, personal communication) . In the therapy of Paget's disease similar doses of etidronate resulted in a signi®cant development of osteoid in pagetic and nonpagetic bone, but these histologic changes were reversible 28, 29 and were not associated with a higher incidence of fracture. 28, 29 The experiments in animals con®rm these clinical observations. Flora et al. reported that higher doses of etidronate can be administered in patients without fear of a fracture problem; 30 their results obtained in adult beagle dogs showed that spontaneous bone fractures develop only when the dose of etidronate was approximately 3 ± 5 times the dose of 20 mg/kg/day used in our study.
Concerning the appearance of HO after cessation of therapy, it has been shown that after withdrawal of medication there was a rapid increase in the growth of heterotopic bone. 17 In contrast to these studies where etidronate was given for 2 months, we were not able to document`rebound' in the appearance of HO after etidronate therapy. A possible explanation for the dierences between these results is the dierence in the total dose of etidronate which was higher in our study and could delay the appearance of`rebound' ossification. Finerman and Stover showed that HO usually appeared in SCI patients on the average of 2 months after therapy. 17 All patients in our study have been followed for more than 2 months and some of them up to 3 years without any evidence of HO on radiographic examination. Since etidronate can ®rmly bind to bone minerals and remain in bound form for an extended period of time 31 it is probably premature, even after several months, to make conclusions about the`rebound' eect and long-term results of our therapeutic protocol.
Alternatively we can speculate that in addition to the eect of etidronate on mineralization, high doses of this drug may also cause changes in the function of cells which are involved in de novo formation of heterotopic bone. It has been demonstrated that etidronate can reduce the number of bone forming cells and alter the cell morphology in an experimental model of HO. 8, 32 The cells in the newly formed tissue had an atypical appearance with histologic characteristics of both osteoblasts and osteocytes and were surrounded with atypical extracellular matrix which contained large amount of clear material and poor collagen ®bers. Several studies extensively examined the eect of etidronate on osteoclasts, 33 ± 35 which also showed morphologic and functional changes. In addition to its eect on the bone cells, etidronate has an antiin¯ammatory eect;
19,36 ± 38 the mechanism of antiin¯ammatory action is unknown, but recent data suggest that it may aect the production of interleukin 1 which plays an important role in pathogenesis of experimentally induced HO. 39, 40 Clinical data indicate that etidronate has a dual eect in the treatment of HO. One eect is extracellular, involving mineralization of bone matrix. The other eect is cellular, involving cells responsible for the formation of HO and in¯ammatory reaction. A better understanding of the role of etidronate in HO, and further investigation of the etiopathogenesis of heterotopic ossi®cation will allow the design of more ecient diagnostic and therapeutic protocols.
In conclusion, the results of this study suggest that our approach in diagnosis and therapy of HO is more eective than those previously reported. Also, bone scintigraphy performed in asymptomatic patients seems to be a sensitive test for the early diagnosis of HO. Finally, etidronate therapy started at the time of scintigraphic diagnosis may prevent the development of HO in the majority of patients.
